Can SIKA Exit Disruption Mode? Q2 Tests Supply-Chain Recovery
After a brutal Q1 (revenue -37% YoY on geopolitical supply chaos), Sika Interplant faces the street's core question: is the worst behind? Q2 results will show whether normalizing supplies translate to demand recovery and margin repair.
The Setup
SIKA Interplant—a mid-cap defence-sector component supplier—reported consolidated revenue of ₹42.86 Cr in Q1 FY27, down 36.98% YoY from ₹68.01 Cr in Q1 FY26, with PAT falling 19% YoY to ₹8.48 Cr (standalone: ₹8.48 Cr). The collapse was attributed to geopolitical supply-chain disruptions that hit parts availability through June. The silver lining: sequential QoQ growth of 3.7% from Q4 FY26's ₹41.33 Cr signalled early recovery momentum entering Q2.
For Q2 (ended Sept 30, 2026), the market will scrutinise two things: (1) whether disruptions continued easing through July–September, allowing sequential recovery to ₹45–50 Cr; and (2) margin repair as supply constraints lift and the company can fulfil pent-up orders at full capacity. Given the Defence sector's structural demand tailwinds, a successful recovery narrative could reset sentiment sharply—but execution risk on normalisation is real.
What to Expect
~₹45–50 Cr
Sequential growth expected if disruptions continue easing; base case assumes supply normalisation through Q2
~₹9–11 Cr
Recovery from Q1 lows as production ramps; depends on capacity utilisation and cost reabsorption
~16–18%
Lower than historical (often 18–22%) due to lingering supply inefficiencies; full normalisation may extend to H2
Unverified against actuals
Company has not issued public FY27 guidance; expect board commentary on H2 trajectory and recovery milestones
A strong Q2 print would show revenue in the ₹50–55 Cr range (evidencing near full-cycle recovery), PAT ≥₹11 Cr, and management commentary confirming supply normalisation is complete—with H2 capex/orders picking up. A weak print would see revenue stalled below ₹45 Cr, margins still compressed below 15%, or cautious H2 guidance suggesting supply headwinds persist. The swing metric: capacity utilisation (unannounced) will be the tell.
On Track?
The company has not published a formal FY27 guidance or multi-quarter roadmap in public disclosures. The core trajectory test is recovery velocity: Q1's 3.7% QoQ growth + easing disruption = expect Q2 to build on that. If Q2 shows flat or negative QoQ sequencing despite lower disruption risk, it signals either (a) sustained end-demand weakness in Defence procurement, or (b) execution missteps. If growth accelerates to 8–12% QoQ, the recovery narrative gains traction and full-year outlook improves materially.
Since Last Quarter
Aug 14, 2026
Q1 FY27 Results; Management Guidance on Disruption
Revenue ₹42.86 Cr (−37% YoY), PAT ₹8.48 Cr (−19% YoY). Supply disruptions quantified as material headwind; partial easing expected into Q2.
Aug 12, 2026
40th Annual General Meeting (AGM)
Routine shareholder annual process; no material changes to governance or capital allocation announced.
Sep 25, 2026
Trading Window Closure (Insider Trading Compliance)
Routine pre-result closure per SEBI (Prohibition of Insider Trading) Regulations. Indicates board is in possession of unpublished results; no insider dealing evident.
Nov 5, 2026
Board Meeting Announcement — Q2 Results Approval
Board scheduled to meet Nov 14, 2026 to approve unaudited Q2 FY27 standalone and consolidated financial statements. Results likely to publish same day or within 48 hrs.
Insider/Promoter Activity: No significant pledging, bulk deals, or insider transactions flagged post-Q1. Promoter holding stable at 71.72% (no change QoQ). FII holding inched up to 3.25% from 3.21%, suggesting modest institutional interest into weakness.
Regulatory & Risk: No material adverse announcements (compliance breaches, contract losses, litigation). The trading window closure is routine and neutral.
Three Things to Watch on Result Day
1 · Sequential Revenue Growth (₹45–50 Cr target)
The headline: if Q2 revenue exceeds ₹50 Cr, the recovery narrative solidifies. Below ₹45 Cr raises concerns on end-demand or further delays. Management commentary on geographic/segment mix (defence vs. civilian) will clarify demand stickiness.
2 · Margin Expansion (PAT % towards 18%+)
Watch for PAT % improvement YoY and QoQ. If margins compress despite higher revenue, it signals either pricing pressure or lingering cost inflation—both red flags. Full normalisation to historical 20%+ territory may not happen until Q3, but a trend toward recovery is critical.
3 · FY27 H2 Guidance & Capex Plans
The board will likely offer commentary on Q3–Q4 demand pipeline and confidence in full-year trajectory. Any colour on Defence Ministry procurement timelines, export orders, or internal capex to boost capacity would be constructive for sentiment. Silence or caution invites nervousness.
SIKA Interplant faces a binary: Q2 validates supply-chain recovery and re-ignites Defence growth momentum, or it signals that disruptions were more entrenched than expected. The Street has thin coverage, so misses will lack sell-side cushioning. Importantly, at ₹916 (down 43.6% from ATH), the risk-reward favours a strong print—but execution delivery is the bar.